In vitro hydrogel-cell model for pharmacokinetic analysis

Inside the human eye, a clear, jelly-like substance fills the space between the lens and the retina, acting as a protective cushion and a transparent window for light. This substance, known as the vitreous humour, is not just water; it is a complex, gel-like network that can trap or slow down anything trying to move through it. When doctors need to treat diseases of the retina, such as diabetic retinopathy or age-related macular degeneration, they often inject medicine directly into this space. However, for the treatment to work, the drug must travel through this thick gel and reach the delicate cells of the retina without getting stuck or breaking apart. Scientists have long struggled to test how well these medicines move in a lab setting, because the environment inside the eye is too complex to copy with simple flat layers of cells, and using real animal eyes is difficult and inconsistent.

To solve this, researchers at the University of Liverpool have built a new kind of test model that mimics the eye's interior with much greater accuracy. Instead of just growing cells in a dish, they created a three-layer system: a layer of living retinal cells, a synthetic gel that behaves like the vitreous humour, and a method to watch tiny particles move through it all without disturbing them. Their goal was to understand how the chemistry of the fluid and the presence of living cells change the way drug carriers, specifically tiny gold particles, travel toward their target. By watching these particles in real time, the team discovered that the journey is far more dynamic than previously thought, with the fluid's composition and the cells themselves creating distinct zones that either help or hinder movement.

The researchers began by addressing a fundamental problem: how proteins in the fluid affect the movement of tiny particles. In the body, particles are constantly surrounded by proteins that stick to their surfaces, forming a temporary coating. The team tested this by placing gold particles, some positively charged and some negatively charged, into two different liquids. One liquid was a basic nutrient solution, while the other was enriched with proteins from blood serum to mimic the biological environment. They found that in the protein-free liquid, the particles tended to clump together over time, slowing their movement significantly. However, in the protein-rich liquid, the proteins acted like a shield, preventing the particles from sticking to each other and allowing them to move freely. This confirmed that the presence of proteins is essential for keeping these drug carriers stable and mobile, a finding that holds true regardless of whether the particles are positively or negatively charged.

Next, the team introduced a living layer of human retinal cells into the mix to see how a biological barrier would change the story. They grew a tight sheet of these cells on a glass slide and placed the gel and particles above them. When they tracked the particles near the cells, they noticed that the environment became much more chaotic. The cells themselves secrete various molecules that interact with the particles, creating a unique, shifting coating that is different from the one formed by proteins alone. This interaction increased the variety in how the particles moved, suggesting that the cells actively modify the path of the drug carriers. Interestingly, the distance from the cell layer mattered less than the presence of the cells themselves; whether the particles were close to the cells or slightly further away, the complexity of the environment remained high, driven by the biological activity of the cells.

The most significant breakthrough came when the researchers combined the living cells with their synthetic gel, which was designed to mimic the vitreous humour. They created a gel using agar and hyaluronic acid, mixed with a small amount of protein-rich fluid to ensure the cells stayed healthy. When they watched the particles move through this complete system, they observed something remarkable: the particles did not all move at the same speed. Instead, they split into two distinct groups. Some particles moved quickly, as if they were swimming in open water, while others moved very slowly, as if they were stuck in a thick mesh. This revealed that the gel is not a uniform block but contains two different micro-environments: an aqueous, water-like phase and a denser, gel-like phase. The particles were able to navigate both, but their speed depended entirely on which phase they happened to be in at that moment.

When the team added the layer of living cells back into this gel system, the distribution of the particles changed again. They found that a large majority of the particles near the cell layer were moving quickly in the water-like phase, suggesting that the cells create a clear, fluid boundary around them. As the particles moved further away from the cells, they were more likely to encounter the slower, gel-like phase. This discovery is crucial because it shows that the interface between the cells and the surrounding fluid is not a solid wall but a dynamic zone where the rules of movement shift. The researchers also noted that the charge of the particles influenced how they behaved in these zones, with negatively charged particles generally maintaining a more fluid path than their positively charged counterparts.

This new model provides a powerful tool for scientists to test how well new drug delivery systems will work before they are ever used on a patient. By replicating the complex layers of the eye—the living cells, the protein-rich fluid, and the gel-like vitreous humour—the researchers can see exactly how a drug carrier will behave in a realistic setting. The study demonstrates that the success of a treatment depends not just on the drug itself, but on how it interacts with the proteins in the fluid and the environment created by the cells. With this understanding, scientists can now design better carriers that are less likely to get stuck and more likely to reach their destination, potentially reducing the number of painful injections patients need for retinal diseases. The work offers a clear, reproducible way to study these interactions, turning a complex biological mystery into a manageable, observable process.